Trine Søndergaard Jensen is an Assistant Professor at Aalborg University's Faculty of Health Sciences, affiliated with the Department of Medicine and Health Technology. Her research focuses on cancer immunotherapy and dendritic cell biology. Research Interests: Optimization of dendritic cell function for enhanced cancer treatment Induction of immunogenic cell death in cancer cells Priming the STING pathway in dendritic cells Addressing tumor-induced immunosuppression Publication Trends (2020-2024): Research spans cancer immunotherapy, dendritic cell activation, and complement system interactions with bacterial pathogens, with recent emphasis on cholesterol metabolism and STING pathway in tumor microenvironment.
Amiram Ariel is an Associate Professor specializing in immunology with a focus on inflammation resolution mechanisms. He serves as Associate Editor for Inflammation at Frontiers in Immunology and Review Editor for Molecular Innate Immunity, demonstrating active scholarly engagement. His research centers on macrophage biology and pro-resolving mediators, investigating their roles in treating inflammatory disorders, fibrosis, cancer metastasis, and diabetic wound healing. Key contributions include elucidating interferon-stimulated neutrophil functions in immunotherapy response and JMJD3/STING pathway interactions in tissue repair. Recent publications (2021-2024) reveal consistent themes: leveraging resolution-phase macrophages against dormant tumor cells, IFN-β-mediated anti-fibrotic effects, and inflammation resolution strategies for COVID-19 pathogenesis. These works bridge molecular immunology with translational applications in oncology and regenerative medicine. No scientific awards are documented in the available materials. While his 53 publications indicate significant scholarly output, details regarding student mentorship, grant funding, or laboratory structure are absent from the provided text. His professional network includes 79 followers and 49 researchers he follows, reflecting active academic collaboration. Dr. Ariel's educational background includes studies at Hebrew University, though specific degrees and years remain unspecified in the source material.
Dr. Ying H Shen, M.D., Ph.D., is a Professor of Surgery at Baylor College of Medicine and serves as the Director of the Aortic Disease Research Laboratory. She is affiliated with the Division of Cardiothoracic Surgery and has joint affiliations with the Texas Heart Institute. Her work bridges clinical surgery and translational vascular biology, with a focus on aortic diseases and diabetic vascular complications. Education: Ph.D. in Biomedical Sciences — University of New South Wales, Sydney, NSW, Australia M.D. — Beijing Medical College, Beijing, China Research Interests: Dr. Shen's research is centered on understanding the molecular mechanisms underlying aortic aneurysms and dissections. Her laboratory investigates signaling pathways that regulate aortic destruction, healing, and remodeling. She has developed innovative mouse models to study these processes and applies advanced techniques to assess aortic structure and function. A key translational goal is the development of pharmacological strategies to prevent progressive aortic disease. She also explores diabetic vascular diseases and the role of inflammation and metabolic dysfunction in vascular biology. Recent Research Trends: Her recent publications (2017–2023) emphasize epigenetic regulation, single-cell transcriptomics, inflammasome signaling, and the role of innate immune pathways such as STING and NLRP3 in aortic degeneration. There is a consistent focus on identifying therapeutic targets for aortic aneurysm and dissection, including the adverse effects of drugs like ciprofloxacin in genetically predisposed individuals. Scientific Awards: Dr. Mark L. Entman Teaching Award for Excellence in Cardiovascular Education (2023) Grants & Funding: Dr. Shen has received major funding from the NHLBI, including an R01 grant awarded jointly with Dr. LeMaire, to study gender differences in aortic disease. Her lab is supported by multiple federal and institutional grants aimed at dissecting the molecular basis of vascular pathology and developing targeted therapies. Laboratory & Team: She directs the Aortic Disease Research Laboratory at Baylor College of Medicine, in collaboration with the Texas Heart Institute. Her team includes postdoctoral fellows, graduate students, and research staff working on translational vascular biology projects.
Luke A. Gilbert is an Assistant Professor in the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco (UCSF), School of Medicine. He leads an independent research program focused on functional genomics, epigenetic engineering, and cancer biology, supported by multiple NIH grants including an R01, DP2, and R41 awards. His research centers on developing and applying CRISPR-based technologies to dissect gene regulation, chromatin dynamics, and cancer vulnerabilities. Key areas include epigenetic memory editing using CRISPRoff, combinatorial chromatin perturbations, and identifying regulatory elements in cancer. His work spans glioblastoma, prostate cancer, and acute myeloid leukemia, with a strong emphasis on therapeutic translation. The recent publications reveal a strong trend in high-throughput functional genomics, single-cell and spatial analyses, and integrative multiomics to uncover mechanisms of drug resistance, immune evasion, and oncogenic signaling. His team leverages cutting-edge tools like perturb-seq and engineered CRISPR systems to interrogate complex biological systems in vivo and in vitro. Scientific Awards: Virginia and Daniel K. Ludwig Graduate Research Fellow Leukemia and Lymphoma Society Postdoctoral Fellow NIH/NCI Pathway to Independence Award Gabrielle's Angel Foundation Medical Research Fellow NIH Director's New Innovator Award (2019–2023) Pew-Stewart Scholar for Cancer Research (2020) AAAS / Martin and Rose Wachtel Cancer Research Award (2022–2023) Prostate Cancer Foundation Challenge Award (2022–2027) CRUK/NCI Cancer Grand Challenge Award (2022–2027) NIH NHGRI UM1 HG012660 Luke Gilbert has secured significant grant funding as Principal Investigator on multiple NIH projects, including a DP2 New Innovator Award and R01 grants focused on DNA methylation editing and genetic interaction mapping in the human nucleus. These grants support his lab’s innovative work in functional genomics and cancer biology. He is actively involved in collaborative science, as seen through his participation in large consortia such as the MorPhiC Consortium, and his research is conducted within state-of-the-art facilities at UCSF, leveraging the university’s strengths in biomedical research, genomics, and translational medicine.
Derek Hayden Oakley, M.D., Ph.D. , is Assistant Professor of Pathology at Massachusetts General Hospital and Harvard Medical School . Based in the Department of Pathology, his laboratory integrates human iPSC-based neuronal models, quantitative 3-D neuropathology, and machine-learning approaches to dissect mechanisms underlying Alzheimer’s disease and related tauopathies. Education & Training M.D. (Doctor of Medicine) Ph.D. (Doctor of Philosophy) Research Interests Dr Oakley’s work focuses on the molecular and cellular basis of neurodegeneration, particularly the pathobiology of tau protein and amyloid-β in Alzheimer’s disease. By leveraging patient-derived induced pluripotent stem cell (iPSC) neurons, he investigates post-translational modifications of tau and their influence on neuronal toxicity and propagation. His group also pioneers the application of machine-learning algorithms to high-resolution dissection photographs and surface scans, enabling objective, quantitative 3-D neuropathological analyses of human brain tissue. A complementary line of research examines the intersection of innate immune signaling—such as STING activation—with neurodegeneration in ALS and frontotemporal dementia. Overall, his studies bridge fundamental mechanistic work with translational biomarker discovery, aiming to accelerate clinical trial readiness in tauopathies and synucleinopathies. Publication Trends Between 2020 and 2025, Dr Oakley co-authored 48 peer-reviewed papers that collectively map the molecular landscape of tau, amyloid, and innate immunity in neurodegeneration. High-impact contributions include Nature (somatic mutations in Alzheimer neurons), Acta Neuropathologica (cryptic splicing signatures of TDP-43 dysfunction), and Science Translational Medicine (cholesterol homeostasis in the living human brain). These works underscore a trajectory from mechanistic discovery towards biomarker and therapeutic target validation. Scientific Awards & Recognition Specific honors are not detailed in the provided text. Research Funding & Collaborative Networks Dr Oakley is embedded in extensive collaborative networks (>100 co-authors) anchored by Massachusetts General Hospital and the Harvard NeuroDiscovery Center. He co-leads projects with Drs Bradley Hyman and Matthew Frosch, and participates in multi-institutional consortia such as the Pick’s Disease International Consortium. His work is supported by federal and foundation grants, though exact funding details are not listed. Laboratory & Affiliations Laboratory location: Massachusetts General Hospital, Pathology, WRN 245 55 Fruit Street, Boston, MA 02114, USA Phone: +1 617-726-1077
Subhash Sinha serves as Professor of Research in Neuroscience at the Brain and Mind Research Institute, Weill Cornell Medical College, Cornell University. His work bridges molecular neuroscience and therapeutic development for neurodegenerative disorders, with emphasis on Alzheimer's disease mechanisms and intervention strategies. His academic foundation includes: B.Sc. from Patna University (India), 1980 M.Sc. from Patna University (India), 1983 Ph.D. from Banaras Hindu University (India), 1988 Dr. Sinha's research integrates molecular biology, immunology, and computational approaches to investigate cGAS-STING pathway dysregulation in neurodegeneration. Key interests include tau pathology mechanisms, microglial senescence, sex-specific demyelination processes, and development of cGAS inhibitors and tau-targeted immunotherapies. His work explores genetic resilience factors like APOE3-R136S and cellular mechanisms underlying cognitive preservation. Analysis of his 15 most recent publications reveals a dominant focus on cGAS inhibition (appearing in 7 articles), tau pathology (10 articles), and neuroinflammation (12 articles). Methodologically, his team employs iPSC models, murine disease systems, high-throughput screening, and molecular modeling to identify therapeutic targets with translational potential for Alzheimer's disease. Dr. Sinha currently leads or co-leads seven major research initiatives including NIH-funded projects on cGAS inhibitors (NIA, 2021-2026) and acetylated tau immunotherapy (NIA, 2025-2026). His grant portfolio spans the Cure Alzheimer’s Fund, Rainwater Charitable Foundation, and Harrington Discovery Institute, focusing on target validation, lead optimization, and disease mechanism studies. He maintains active industry collaborations as Consultant for Aeton Therapeutics Inc. and CGA Therapeuticals Incorporated, and holds Leadership Roles at LSG Therapeutics, LLC, facilitating translation of academic discoveries into therapeutic pipelines.
Li Fan is an Instructor in Neuroscience at the Brain and Mind Research Institute, Weill Cornell Medical College , a position she has held since 2022. Her work bridges cutting-edge single-cell genomics with neuroimmunology to understand how microglia and molecular pathways drive neurodegeneration, particularly in Alzheimer’s disease and related tauopathies. Education Ph.D., Lanzhou University (China), 2012 B.A., Tianshui Normal University (China), 2007 Research Interests Dr. Fan’s research integrates multi-omics single-cell profiling , microglial biology , and neuroimmunology to dissect mechanisms underlying Alzheimer’s disease, frontotemporal dementia, and sex-specific brain aging. She probes how risk alleles, epigenomic states, and innate immune signaling (e.g., cGAS-STING, NF-κB, TLR7) modulate microglial phenotypes, tau propagation, and myelin integrity across brain regions and disease stages. Publication Themes Across her 15 most recent papers (2020-2025) she interrogates four intertwined themes: (1) microglial senescence and cGAS-STING-IFN signaling as drivers of tau-mediated neurodegeneration; (2) discovery of protective genetic variants such as the APOE3-R136S mutation; (3) single-cell chromatin-transcriptome and splicing atlases of human and mouse brain; and (4) sex-specific immune mechanisms (TLR7, X-linked factors) governing demyelination in aging and Alzheimer’s disease. Scientific Awards & Honors No awards explicitly listed in the provided text. Advising & Grants No specific students, grant numbers, or funding agencies are mentioned in the text. Laboratory & Team Information Details of her laboratory, research group members, or future projects have not been disclosed in the supplied material.
Li Gan, Ph.D., is the Burton P. and Judith B. Resnick Distinguished Professor in Neurodegenerative Diseases at the Brain and Mind Research Institute, Weill Cornell Medical College. Since 2018 she has led an interdisciplinary program that integrates human iPSC-based disease modeling, single-cell multi-omics, and therapeutic target discovery to combat Alzheimer’s disease and related tauopathies. Education Ph.D., Yale University School of Medicine (1996) B.S., Peking University, China (1990) Research Focus Dr. Gan’s laboratory investigates how microglial innate immunity, tau post-translational modifications, and sex-specific pathways drive neurodegeneration. Using CRISPR-engineered human induced pluripotent stem cell (iPSC) models, brain organoids, and chimeric mouse brains, her team decodes cell-type-specific vulnerabilities and designs first-in-class therapeutics—including cGAS inhibitors, anti-acetyl-tau antibodies, and small-molecule modulators of microglial homeostasis. Grants & Support NIA “Mapping proteomic changes of tauopathy in human neurons” (PI, 2025-2030) Cure Alzheimer’s Fund “Sex-biased TLR7 signaling” (PI, 2025) NIA “Acetylated Tau Immunotherapy” (PI Subaward, 2025-2026) JPB Foundation “Targeting maladaptive innate immune response” (PI, 2024-2027) Rainwater Charitable Foundation series on cGAS inhibitors and 4R tauopathy models (PI, 2024-2025) Chan Zuckerberg Initiative & Ludwig Family Foundation awards for neuro-immune resilience studies Industry & Advisory Roles Dr. Gan serves as Scientific Advisory Board Member for Arvinas, Inc. and Neurovanda Therapeutics; consultant to Aeton Therapeutics, LSG Therapeutics, and NeuroLambda Therapeutics; and maintains equity/proprietary interests in these companies plus Retro Biosciences, reflecting long-standing translational collaborations. Laboratory & Teams The Gan Lab operates within the Brain and Mind Research Institute’s state-of-the-art facilities, hosting post-doctoral fellows, graduate students, and research technicians focused on high-throughput CRISPRi/a screening, single-cell epigenomics, and pre-clinical testing of therapeutic leads. Active partnerships extend to the NIH-funded Alzheimer’s Disease Tau Platform Clinical Trial Network and international open-science consortia.
Ru-Rong Ji is the William Maixner Professor of Anesthesiology at Duke University School of Medicine, with additional professorships in Neurobiology and Cell Biology. He serves as Director of the Center for Translational Pain Medicine and is a Faculty Network Member of the Duke Institute for Brain Sciences. His extensive academic career spans over 25 years across multiple prestigious institutions including Duke University (2012-present), Harvard Medical School (1998-2012), Johns Hopkins Medical School, Karolinska Institute, and Peking University. Dr. Ji's research focuses on identifying molecular and cellular mechanisms underlying pathological pain and developing novel pain therapeutics. His work centers on neuroimmune interactions, with specific interests in: How inflammation induces and resolves pain through immune cell interactions with sensory neurons Neuroinflammation driving chronic pain via glial cell activation in CNS and PNS Specialized pro-resolution mediators (SPMs) controlling pain through GPCR signaling Immunotherapies regulating pain through PD-L1/PD-1 and STING/IFN pathways Secreted miRNAs regulating pain via surface receptors and ion channels Nerve terminal interactions with cancers in chronic pain and itch Toll-like receptors in sensory neurons sensing danger signals Regenerative approaches for long-term pain relief His recent publications show a strong trend toward translational pain research, with emphasis on neuroimmune mechanisms, specialized pro-resolving mediators, and novel therapeutic targets. Dr. Ji's work spans multiple pain conditions including chemotherapy-induced neuropathy, postoperative pain, inflammatory pain, neuropathic pain, and cancer-related pain, demonstrating a comprehensive approach to understanding pain mechanisms across diverse conditions. Dr. Ji has been recognized as a Highly Cited Researcher by Clarivate Analytics (Cross Field), reflecting his significant impact in the field. His research has led to numerous patents for translational studies in pain management. As Director of the Center for Translational Pain Medicine, Dr. Ji provides scientific and administrative leadership for research projects. His lab employs a multidisciplinary approach combining in vitro, ex vivo, and in vivo studies including animal behaviors, electrophysiology, molecular biology, cell biology, and transgenic animal models. His work has identified numerous therapeutic targets for pain management. Dr. Ji leads the Center for Translational Pain Medicine at Duke, fostering collaboration across disciplines to advance pain research from bench to bedside. His team integrates expertise in neuroscience, immunology, molecular biology, and clinical pain management to develop innovative approaches for treating chronic pain conditions.
Dr. Stefan Muljo serves as Chief of the Integrative Immunobiology Section within the Laboratory of Immune System Biology at the National Institutes of Health (NIH). Appointed as a tenure-track investigator in 2008 and promoted to tenured Senior Investigator in 2016, he leads a research program focused on understanding post-transcriptional regulation of immune system development. His section is part of NIAID's Division of Intramural Research located at the NIH Main Campus in Bethesda, MD. Dr. Muljo earned his Ph.D. from The Johns Hopkins University School of Medicine, with dissertation work partially conducted at UC Berkeley. Following a postdoctoral fellowship at Harvard Medical School's Immune Disease Institute, he joined NIAID in 2008. He currently serves as faculty for the NIH-OxCam and NIH-Penn graduate partnership programs, mentoring the next generation of immunologists and RNA biologists. His research centers on RNA biology within the immune system, specifically investigating how gene expression programs are regulated post-transcriptionally through RNA-binding proteins, long non-coding RNAs, and microRNAs. Key research areas include hematopoietic stem cell differentiation, fetal versus adult hematopoiesis, regulation of human endogenous retroviruses, and the function of innate-like B-1 cells. His work has identified important molecular players like Lin28b as lineage-determining factors for fetal hematopoietic stem cells, with significant implications for regenerative medicine. Analysis of Dr. Muljo's publication record reveals consistent contributions to understanding post-transcriptional regulation in immunology, with recent work focusing on RNA-binding proteins like MATRIN3 and RBM4, macrophage polarization in allergy, and B lymphocyte development. His research spans fundamental mechanisms of gene regulation to potential therapeutic applications, particularly in manipulating microRNAs for immune modulation. Dr. Muljo actively participates in training through the NIH-OxCam Partnership Program, offering joint doctoral studentships to study fetal hematopoiesis in both mouse models and human systems. His laboratory employs an integrative systems biology approach combining genome-wide measurements with experimental perturbations to reverse engineer molecular logic of cellular differentiation. His laboratory maintains an active research program investigating how post-transcriptional regulation contributes to immune system development and function, with particular interest in translating basic discoveries to improve human health, especially for conditions like sickle cell disease and beta-thalassemia. The section's work on fetal hemoglobin production has led to a pending patent application with potential therapeutic applications.
Diana N Obanda serves as Assistant Professor in the Department of Nutrition & Food Science at the University of Maryland's College of Agriculture and Natural Resources, with research conducted from the Skinner Building in College Park. Her dual PhD qualifications in Environmental Science (2008) and Molecular Nutrition (2017) both originate from Louisiana State University. Her educational pathway includes: BSc from Moi University, Kenya MS in Environmental Science from Louisiana State University PhD in Environmental Science (2008) PhD in Nutrition & Food Science (2017) Dr. Obanda's research centers on cellular/molecular nutrient mechanisms, specifically investigating how food and medicinal plant compounds modulate obesity pathways, gut microbiota composition, and intestinal immune function. She examines gene expression alterations in metabolic tissues (skeletal muscle, adipose, intestinal) driving insulin resistance, while developing functional food interventions for obesity-related dysbiosis and inflammation. Her work bridges nutritional biochemistry with translational metabolic health applications. Analysis of her 2016-2021 publications reveals consistent focus on Urtica dioica (stinging nettle) and kale compounds in rodent obesity models. These studies demonstrate how plant interventions reshape gut microbiome architecture (particularly Clostridia populations), reduce inflammation, and improve insulin sensitivity through molecular pathways like PP2A activation and ceramide regulation. The research trajectory shows progressive mechanistic depth from whole-vegetable effects to adipocyte-level signaling. No scientific awards or fellowships were documented in the source material. As Principal Investigator for USDA-NIFA Grant 13066033 and Maryland State Agricultural Experiment Station Grant MD-NFSC-211757, she directs research on functional foods for metabolic disorders. Her teaching portfolio includes NFSC 450 (Food and Nutrient Analysis), NFSC 423 (Food Chemistry Laboratory), and NFSC 678K (Gut Microbiota in Obesity), reflecting integration of research themes into advanced coursework despite no listed advisees. Her laboratory operations appear centered on molecular nutrition techniques for gut-microbiome-metabolism interactions, likely maintaining collaborative ties with Pennington Biomedical Research Center where she completed postdoctoral training focused on plant compounds for metabolic syndrome prevention.
Bernt Eric Uhlin serves as a Professor at Umeå University's Department of Molecular Biology, where he leads his research group located at 6K and 6L in the Hospital area of Umeå. His work spans bacterial pathogenesis, molecular microbiology, and infection biology with a focus on host-pathogen interactions. His research centers on understanding bacterial fitness mechanisms in pathogenic Escherichia coli variants and the opportunistic pathogen Acinetobacter baumannii . Specifically, his team investigates molecular mechanisms behind gene expression and function that contribute to bacterial interactions with host environments. This includes studies on biofilm formation, membrane vesicles, virulence factors, and antibiotic resistance mechanisms that allow these pathogens to thrive in challenging conditions. His publication record demonstrates consistent high-impact contributions to microbiology, with recent work spanning bacterial toxins, host-pathogen interactions, and antimicrobial resistance. His research shows particular strength in connecting molecular mechanisms to clinical implications, especially regarding emerging superbugs. Forska!Sverige Honorary Award for extraordinary commitment to creating an excellent research environment Honorary award from the Royal Court for contributions to the development of microbiological research As head of the Bernt Eric Uhlin Lab and participant in the Umeå Extracellular Vesicle Network and Coalition Umeå for Life Science (CU4LS), he actively contributes to collaborative research initiatives. His group's work on nanoplastics' impact on antibiotic effectiveness demonstrates engagement with contemporary environmental health issues. The lab maintains active collaborations across multiple institutions, as evidenced by the international co-authorship on his publications.
Dr. Vilma Yuzbasiyan-Gurkan is a Professor in the Department of Microbiology, Genetics, & Immunology at Michigan State University (MSU). Her research bridges comparative oncology, veterinary genetics, and human disease models, focusing on genetic disorders and cancers in companion animals. Education: B.A., 1978, Vassar College Ph.D., 1983, University of Istanbul Medical School Postdoctoral, 1984-1988, University of Michigan Research Interests: Dr. Yuzbasiyan-Gurkan's work spans comparative oncology and genetic disease modeling , particularly in canine and feline populations. Key areas include mutation discovery (e.g., KIT , PTPN11 ), targeted therapy development (e.g., MEK inhibitors ), and epigenetic profiling of cancers. Her lab emphasizes translational applications, such as liquid biopsy for early detection and microRNA-based treatments for metastatic disease. Article Trends: Her publications reflect a focus on comparative genomics (e.g., KRAS/PTPN11 mutations), epigenetic mechanisms (e.g., methylation patterns), and novel therapeutics (e.g., STING activators, proteasome modulators). Collaborations with chemists (Dr. Jetze Tepe), vaccinologists (Dr. Xuefei Huang), and biomedical engineers (Dr. Anna Moore) underscore interdisciplinary approaches. Collaborative Grants: Dr. Yuzbasiyan-Gurkan has secured funding for multi-omics studies of genetic diseases, comparative cancer trials , and veterinary-student training programs (e.g., BRUSH summer initiative). Her work frequently explores zoonotic parallels between animal and human oncology. Labs & Teams: She leads a team at the 5172 Biomed Phys Sci facility at MSU, integrating genomics, molecular biology, and clinical trials. Her lab collaborates with veterinary practitioners, pharmaceutical researchers, and computational biologists to refine animal models of human disease .
Dr. Trista E. North serves as Co-Director of the Developmental and Regenerative Biology Program and Associate Professor of Pediatrics at Harvard Medical School. She leads the North Lab within the Stem Cell Program and Department of Hematology/Oncology at Boston Children's Hospital, where her research focuses on developmental hematopoiesis and stem cell function. Dr. North is also affiliated with the Harvard Stem Cell Institute and the Department of Stem Cell and Regenerative Biology at Harvard University. B.A. in Biology and Psychology from Bowdoin College (1996) Ph.D. from Dartmouth College (2002) working with Dr. Nancy A. Speck on Runx1's role in hematopoietic stem cell development Postdoctoral research with Dr. Leonard I. Zon at Boston Children's Hospital Dr. North's research explores how extrinsic and environmental cues guide hematopoietic stem cell (HSC) formation, self-renewal, and tissue regeneration. Her lab combines genetic methods and chemical biology approaches in zebrafish embryos with transcriptomics and high-resolution microscopy to identify pathways regulating HSC induction, expansion, and differentiation. Current research focuses on oxygen and glucose metabolism, mechanical cues from blood flow, inflammatory signaling, and epigenetic regulation in HSC development. The lab employs ex vivo murine tissue explant studies, human induced pluripotent stem cell cultures, and in vivo functional analyses including injury/recovery models and HSC transplantation assays. Analysis of Dr. North's recent publications reveals a strong focus on the molecular mechanisms controlling hematopoietic stem cell fate decisions during embryonic development. Her work spans multiple model systems including zebrafish, mouse, and human cell cultures, with particular emphasis on the role of epigenetic regulators (EZH1/2), biomechanical forces (YAP signaling), metabolic regulation of inflammasome activity, and extracellular matrix components in HSC production. A recurring theme is the translational potential of these findings for improving HSC production in culture for clinical applications. Dr. North pioneered a bioactive chemical screening approach in zebrafish that led to the first FDA approval for clinical investigational use of a zebrafish research-derived compound (Prostaglandin E2). She serves on the Executive Board of the Zebrafish Disease Models Society as Treasurer and is an active member of the American Society of Hematology Scientific Committee on Stem Cells and Regeneration. Dr. North has successfully mentored numerous trainees who have secured independent funding (NIH, NSF, CIHR) and presented at major conferences. All PhD trainees in her lab have graduated within 5 years with at least one first-author publication. Her lab members participate in weekly lab meetings, zebrafish group meetings, and individual career mentorship sessions. Undergraduate and technician staff consistently transition to graduate or medical school programs. The North Lab maintains collaborative relationships with multiple research groups including the Daley, Zon, and Goessling labs, and utilizes shared resources through the Harvard Stem Cell Institute. The North Lab operates a sophisticated zebrafish facility supporting their research on hematopoietic development. Lab members include postdoctoral fellows, graduate students, research technicians, and undergraduate researchers working on complementary projects that collectively investigate the environmental and molecular cues guiding hematopoietic stem cell formation. The lab participates in the Boston Children's Hospital zebrafish community and collaborates with clinical researchers to translate basic findings into potential therapeutic applications for blood disorders.
Katherine A. Fitzgerald is a Professor and Vice Chair of Medicine at UMass Chan Medical School, where she also serves as Chief of the Division of Innate Immunity and holds the Worcester Foundation for Biomedical Research Chair III. She has joint appointments in the T.H. Chan School of Medicine, the Morningside Graduate School of Biomedical Sciences across multiple departments including Immunology and Microbiology, Interdisciplinary Graduate Program, MD/PhD Program, Postbaccalaureate Research Education Program, and Translational Science. UMass Chan Medical School, Department of Medicine T.H. Chan School of Medicine Morningside Graduate School of Biomedical Sciences Dr. Fitzgerald received her B.Sc. in Biochemistry in 1995 from University College Cork, Ireland and her PhD in Biochemistry in 1999 from Trinity College Dublin, Ireland. After completing a post-doctoral fellowship at Trinity College Dublin, she joined UMass Chan as an Instructor and has since become a tenured Professor, establishing herself as a leading researcher in innate immunity. Dr. Fitzgerald's research focuses on the innate immune system, specifically investigating the molecular basis of inflammatory responses during infection and in inflammatory diseases. Her laboratory studies nucleic acid sensors, inflammasomes, and long non-coding RNAs in immunity and inflammation. The overarching goal of her work is to determine how innate immune sensing and signaling contribute to infectious, inflammatory, and autoimmune diseases in humans. Her expertise spans multiple areas including the cGAS-STING pathway, inflammasome activation, and the role of non-coding RNAs in immune regulation. Analysis of Dr. Fitzgerald's recent publications reveals a strong focus on the cGAS-STING pathway and its role in various disease contexts, including viral infections, autoimmune conditions, and cancer. Her work also prominently features research on inflammasomes, pyroptosis, and the role of long non-coding RNAs in immune regulation. There is a clear translational emphasis in her research, with multiple studies exploring therapeutic applications of modulating innate immune pathways. Dr. Fitzgerald has received numerous prestigious awards and honors for her contributions to immunology: 2022 Thermofischer Meritorious Career Award, American Association of Immunologists 2021 Elected Member, National Academy of Sciences 2021 Elected member, National Academy of Medicine 2020 Elected member, Royal Irish Academy 2020 Elected Fellow, American Academy of Microbiology 2018 Women in Science and Health Achievement Award 2018 Alumni Achievement Award, University College Cork 2015 Saint Patricks Day Medal 2014 Milstein Award for Excellence in Interferon and Cytokine research Dr. Fitzgerald has extensive service both locally at UMass Chan and nationally, including service on the Massachusetts Center For Pathogen Readiness, NIAID Board of Scientific Councillors, Burroughs Wellcome Fund Pathogenesis of Infectious Diseases, and the Cancer Research Institute. She previously served as President of the International Cytokine and Interferon Society. Her laboratory actively welcomes graduate students and postdoctoral fellows, with rotation opportunities available through the various graduate programs at UMass Chan. Dr. Fitzgerald leads the Program in Innate Immunity at UMass Chan Medical School, which brings together researchers studying various aspects of innate immune recognition and signaling. Her laboratory is at the forefront of research on DNA sensing pathways, inflammasome biology, and the role of non-coding RNAs in immune regulation, with findings that have significant implications for understanding and treating infectious, inflammatory, and autoimmune diseases.
